Considering an extended car warranty but not sure which one is best? Learn about CarShield and Carchex, how they compare, and which is right for you.
BOCA RATON, Fla.--(BUSINESS WIRE)-- #Boyd--Boyd Completes Thermal Business Sale to Eaton for $9.5B, Will Continue to Scale Engineered Materials Business in High Growth Markets
Strengthens iSpecimen’s next-generation marketplace platformWoburn, MA, March 12, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (the "Company”) (NASDAQ: ISPC), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network.The internally developed AI agent analyzes incoming request criteria and is designed to identify potential biospecimen matches, enabling the iSpecimen team to respond to research inquiries with greater speed and precision. By automating the initial review and matching workflow, the technology may reduce manual workload while preserving rigorous expert oversight, ensuring quality and compliance remain paramount.The AI-powered Inventory Agent is natively embedded within iSpecimen’s newly redesigned marketplace platform and powered by large language models (LLMs). Through an intuitive conversational interface, users can submit biospecimen requests in plain language. The system automatically extracts key criteria, including disease conditions, sample types, and diagnostic test requirements, and dynamically searches across configured inventory sources to surface potential matches. Results are ranked by relevance and presented with comprehensive supporting details, empowering the iSpecimen team to evaluate candidate biospecimens quickly and confidently."Optimizing the marketplace for human biospecimens has been the founding mission of iSpecimen since day one. The launch of our AI agent marks a significant milestone in that journey, one that we believe will meaningfully enhance outcomes for our suppliers, our customers, and ultimately the researchers advancing scientific discovery around the world,” commented Katie Field, Chief Executive Officer.This launch represents the first in a series of planned AI-driven capabilities designed to modernize the end-to-end biospecimen sourcing experience. Building on this foundation, iSpecimen expects to introduce features including automated monitoring and validation of regulatory submissions, further automation of high-compliance and data-intensive workflows, and intelligent lead qualification and outreach management, all aimed at reducing friction and accelerating access to critical research samples.Together, these advancements underscore iSpecimen’s commitment to harnessing cutting-edge technology to serve the evolving needs of the global research community.About iSpecimeniSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company’s platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes.Forward Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may,” "will,” "expect,” "intend,” "anticipate,” "believe,” "estimate” and "continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including risks related to the development, performance, and adoption, and regulatory environment applicable to artificial intelligence technologies. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For more information, visit www.ispecimen.comMedia Contactinfo@ispecimen.com
Mexico considers adopting Australia-style social media restrictions for minors to protect children from excessive screen time and harmful online content.
Exceptionally rare sighting of planets colliding may shed light on the crash that formed the moon Live ScienceAstronomers collect rare evidence of two planets colliding Phys.orgStar-struck twice Astronomy MagazineWe May Have Just Seen A Planet Across The Galaxy Get Its Own Version Of Our Moon IFLScienceAstronomers Capture Rare Evidence of Two Planets Colliding vocal.media
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026;continued enrollment in breast cancer triplet combinations -- Next-generation PI3Kα pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026-- Approximately $59M in cash and cash equivalents at the end of Q4 2025BOULDER, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent business highlights."We are pleased with the continued progress across our PI3Kα‐focused pipeline, including the steady execution of the PIKture‐01 trial of OKI-219. We look forward to sharing updated data from this trial later this month,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure. "We are also excited to announce our next‐generation pan‐mutant inhibitor development candidate for HR+ metastatic breast cancer this month and provide additional information on our program in vascular malformations later this year. Overall, we believe our progress to date underscores the power of our mutation‐selective approach to PI3Kα inhibition and reinforces the momentum we are building as we work to deliver scientifically differentiated therapies to patients.”OKI-219 Program HighlightsOnKure’s lead product candidate, OKI-219, is a highly selective PI3kαH1047 mutant specific inhibitor. OKI-219 is being evaluated in the PIKture-01 phase 1a/1b clinical trial for the treatment of patients with HR+ and HER2+ metastatic breast cancer.Parts A and B - Enrollment in both the monotherapy and fulvestrant combination dose escalation arms of the PIKture-01 trial has been completed and closed. A total of 71 patients have been dosed across both arms: 38 in monotherapy and 33 in combination with fulvestrant. The Company expects to report updated safety, tolerability, and clinical activity data from Parts A and B in March 2026.Part E - The Company continues to enroll patients with PI3KαH1047R mutated, HR+ metastatic breast cancer in the triplet expansion arm evaluating OKI-219 in combination with fulvestrant and ribociclib. A total of 17 patients have been dosed with OKI-219 in combination with fulvestrant and ribociclib. The Company expects to report initial safety, tolerability, and clinical activity data from Part E in March 2026.Part C - The Company continues to enroll patients with PI3KαH1047R mutated, HER2+ breast cancer in the triplet expansion arm evaluating OKI-219 in combination with trastuzumab and tucatinib. The Company expects to report initial data from Part C in 2026.Next-Generation PI3KαPAN Mutant Selective ProgramOnKure expects to announce its next-generation PI3Kα pan-mutant inhibitor candidate for HR+ metastatic breast cancer in March 2026.Additionally, PI3Kα mutations represent the most common driver alterations in key subtypes of vascular malformations, where activating PIK3CA variants lead to dysregulated signaling that promotes abnormal cell growth, proliferation, and survival. OnKure believes its differentiated portfolio of PI3Kα inhibitors has significant potential to address a large and underserved patient population. The Company expects to provide additional details on its PI3Kα pan‐mutant program in 2026. This progression reflects the Company’s strategic expansion into indications driven by PI3Kα biology.Financial ResultsCash and cash equivalents were approximately $59.1 million as of December 31, 2025.Research and development (R&D) expenses were $10.7 million for the fourth quarter of 2025, compared to $14.4 million for the fourth quarter of 2024. The decrease of $3.6 million was primarily driven by a decrease in consulting, outsourced R&D, clinical trial, and manufacturing related expenses in addition to lower personnel-related costs.General and Administrative (G&A) expenses were $3.4 million for the fourth quarter of 2025, compared to $4.3 million for the fourth quarter of 2024. The decrease of $0.9 million was primarily driven by a decrease in personnel-related costs and consulting and professional service expenses including audit, tax, insurance, board of director compensation, and other consulting expenses.Net loss and net loss per share for the fourth quarter of 2025 were $13.5 million, or $0.99 per share, compared to $17.4 million, or $1.37 per share, for the fourth quarter of 2024.About PIKture-01 StudyPIKture-01 is a global, multi-center, dose-escalation, first-in-human phase 1a/1b study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) of the study is investigating escalating doses of OKI-219 monotherapy, and Phase 1b is currently investigating OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met. Additional information about PIKture-01 may be found at www.ClinicalTrials.gov, using Identifier: NCT06239467.About OnKure TherapeuticsOnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases. OnKure is currently developing OKI-219, a highly selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, OnKure’s product candidates and programs, including OKI-219 and the pan-mutant program; OnKure’s ability to advance additional programs; the expected milestones and timing of such milestones, including additional data for OKI-219 from the PIKture-01 trial, the anticipated development candidate announcement and details on the pan-mutant program; statements regarding OnKure’s financial position, including its liquidity, cash runway and the sufficiency of its cash resources; and statements by OnKure’s President and Chief Executive Officer. In some cases, you can identify forward-looking statements by terminology such as "estimate,” "intend,” "may,” "plan,” "potentially” "will” or the negative of these terms or other similar expressions.We based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, OnKure’s limited operating history; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the risk that actual uses of cash and cash equivalents differ from the assumptions underlying our expected cash runway; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, OnKure’s product candidates; the outcome of preclinical testing and early clinical trials for OnKure’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements and the potential that the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials; OnKure’s limited resources; the risk of adverse events, toxicities or other undesirable side effects; potential delays or difficulties in the enrollment or maintenance of patients in clinical trials; the decision to develop or seek strategic collaborations to develop OnKure’s current or future product candidates in combination with other therapies and the cost of combination therapies; OnKure’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the substantial competition OnKure faces in discovering, developing, or commercializing products; OnKure’s ability to protect its intellectual property and proprietary technologies; developments relating to OnKure’s competitors and its industry, including competing product candidates and therapies; reliance on third parties, contract manufacturers, and contract research organizations; legislative, regulatory, political and economic developments and general market conditions; and those risks described in the section entitled "Risk Factors” in documents that OnKure files from time to time with the Securities and Exchange Commission ("SEC”), including our Annual Report on Form 10-K filed with the SEC on March 12, 2026 and any subsequent filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.Contact:Dan FerryLifeSci Advisorsdaniel@lifesciadvisors.com ONKURE THERAPEUTICS, INC.Consolidated Condensed Balance Sheets(In thousands, unaudited) December 31,2025 December 31,2024 Assets Current assets: Cash and cash equivalents $59,050 $110,761 Prepaid expenses and other current assets 1,789 2,242 Total current assets 60,839 113,003 Property and equipment, net 618 1,025 Operating lease, right-of-use asset 387 770 Other assets 273 109 Total assets $62,117 $114,907 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable, accrued expenses, and other liabilities $5,372 $9,994 Operating lease liabilities, current portion 549 536 Total current liabilities 5,921 10,530 Long-term liabilities 12 549 Total liabilities 5,933 11,079 Stockholders’ equity 56,184 103,828 Total liabilities and stockholders’ equity $62,117 $114,907 ONKURE THERAPEUTICS, INC.Consolidated Condensed Statements of Operations and Comprehensive Loss(In thousands, except share and per share data, unaudited) Three Months Ended Years Ended December 31, December 31, 2025 2024 2025 2024Operating expenses: Research and development$10,720 $14,361 $48,260 $43,795 General and administrative 3,405 4,338 14,690 10,591 Total operating expenses 14,125 18,699 62,950 54,386 Loss from operations (14,125) (18,699) (62,950) (54,386)Total other income and (expense), net 622 1,257 3,433 1,713 Net loss and comprehensive loss$(13,503) $(17,442) $(59,517) $(52,673) Net loss per share attributable to common stockholders: Basic and diluted$(0.99) $(1.37) $(4.40) $(15.28)Weighted average shares outstanding: Basic and diluted 13,597,287 12,774,553 13,515,915 3,447,071
Elon Musk's Tesla and xAI have launched "Macrohard" (or "Digital Optimus"), an agentic AI system capable of autonomous computer actions. This joint project utilizes Tesla's AI4 chip and xAI's Nvidia hardware, with Grok acting as the navigator and a Tesla AI agent executing tasks. Musk highlighted its potential to emulate entire companies, marking a significant advancement in real-time smart AI.
Rivian showcased its upcoming R2 electric SUV at SXSW in Austin with a temporary off-road course. The vehicle is expected to start at $57,990.
Galactic islands of tranquility: 'Little red dots' may have brewed life's building blocks Phys.org
New study of global reef growth over past 12,000 years offers insights into impact of rising ocean temperatures Phys.orgMoorea Coral Reef Recovery Stalls, Mostly Dead Mirage NewsHeat-tolerant corals may help some reefs persist, but most still erode Phys.org
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
